ONCOLYS BIOPHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 706 JPY | -0.56% |
|
+2.92% | +24.51% |
Income Statement Evolution (Annual data)
| Fiscal Period: |
|---|
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 Q3 | 2021 Q1 | 2021 Q3 | 2022 Q1 | 2022 Q3 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Net sales 1 | 71 | 62 | 125 | 193 | 358 | 35 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -507 | -349 | -330 | -384 | -279 | -325 |
| Operating Margin | -714.08% | -562.9% | -264% | -198.96% | -77.93% | -928.57% |
| Earnings before Tax (EBT) 1 | -880 | -349 | -327 | -328 | -264 | -322 |
| Net income 1 | -881 | -350 | -329 | -328 | -265 | -323 |
| Net margin | -1,240.85% | -564.52% | -263.2% | -169.95% | -74.02% | -922.86% |
| EPS 2 | -61.21 | -22.36 | -18.97 | -18.98 | -15.28 | -18.69 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/6/20 | 5/7/21 | 11/5/21 | 5/13/22 | 11/4/22 | 5/12/23 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: |
|---|
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +24.51% | 95.81M | |
| -3.79% | 87.06B | |
| +1.97% | 40.25B | |
| -17.08% | 31.09B | |
| +52.66% | 24.74B | |
| -13.61% | 15.91B | |
| -9.12% | 11.96B | |
| -15.55% | 11.92B | |
| -42.56% | 11.61B | |
| +4.27% | 8.73B |
- Stock Market
- Equities
- 4588 Stock
- Financials Oncolys BioPharma Inc.
